Alle Fotos(1)
Wichtige Dokumente
W2020
WR-1065
≥98% (HPLC)
Synonym(e):
2-[(3-Aminopropyl)-amino]-ethanthiol -dihydrochlorid
Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)
About This Item
Empirische Formel (Hill-System):
C5H14N2S · 2HCl
CAS-Nummer:
Molekulargewicht:
207.16
MDL-Nummer:
UNSPSC-Code:
12352200
PubChem Substanz-ID:
NACRES:
NA.77
Empfohlene Produkte
Qualitätsniveau
Assay
≥98% (HPLC)
Form
powder
Lagerbedingungen
desiccated
Farbe
white to off-white
Löslichkeit
H2O: ≥20 mg/mL
Lagertemp.
−20°C
SMILES String
Cl.Cl.NCCCNCCS
InChI
1S/C5H14N2S.2ClH/c6-2-1-3-7-4-5-8;;/h7-8H,1-6H2;2*1H
InChIKey
XDRLRDHLCIFZIW-UHFFFAOYSA-N
Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich
Biochem./physiol. Wirkung
WR-1065 is cytoprotective cell-permeable reactive oxygen species scavenger and p53 activator and re-activator. Recently shown to have antiretroviral activity and an active metabolite of Amifostine which selectively protects normal tissues from the damaging effects of anti-neoplastic radiation therapy.
WR-1065 is the active metabolite of the prodrug amifostine, generated by alkaline phosphatase. It is found to accumulate in many epithelial tissues. WR-1065 protects cellular membranes and DNA from free radical induced damage.
Signalwort
Danger
H-Sätze
Gefahreneinstufungen
Acute Tox. 4 Oral - Eye Dam. 1
Lagerklassenschlüssel
11 - Combustible Solids
WGK
WGK 3
Flammpunkt (°F)
Not applicable
Flammpunkt (°C)
Not applicable
Hier finden Sie alle aktuellen Versionen:
Besitzen Sie dieses Produkt bereits?
In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.
Kunden haben sich ebenfalls angesehen
Jeffrey S Murley et al.
Radiation research, 167(4), 465-474 (2007-03-29)
RKO36 cells, a subclone of RKO colorectal carcinoma cells that have been stably transfected with the pCMV-EGFP2Xho vector, were grown to confluence and then exposed to either the radioprotector WR-1065, i.e. the active thiol form of amifostine, for 30 min
Amifostine: the first selective-target and broad-spectrum radioprotector
Kouvaris JR, et al.
Oncologist, 12(6), 738-747 (2007)
Trevor McKibbin et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 16(3), 1049-1057 (2010-01-28)
We evaluated the pharmacokinetics of amifostine and WR1065 in pediatric patients with newly diagnosed medulloblastoma to assess the influence of patient covariates, including demographics, clinical characteristics, and genetic polymorphisms, on amifostine and WR1065 pharmacokinetic parameters. We assessed the pharmacokinetics of
Jeffrey S Murley et al.
Radiation research, 175(1), 57-65 (2010-12-24)
RKO36 cells exposed to either WR1065 or 10 cGy X rays show elevated SOD2 gene expression and SOD2 enzymatic activity. Cells challenged at this time with 2 Gy exhibit enhanced radiation resistance. This phenomenon has been identified as a delayed
Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly: A prospective randomized study in squamous cell head and neck cancer
Jellema AP, et al.
Cancer, 107(3), 544-553 (2006)
Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..
Setzen Sie sich mit dem technischen Dienst in Verbindung.